Despite an immediate need for more regulatory guidance and consumer safety provisions, the FDA has decided to punt any regulatory guidance with regard to CBD back to Congress. While the FDA has acknowledged the need for a new pathway to regulate these produces, it announced today that the current regulatory framework does not provide sufficient protections to regulate CBD. While they are working on a solution, this continued delay presents major concerns for manufacturers, consumers, advocates and stakeholders.
| less than a minute read
FDA Determined it Will Not Regulate CBD in Food or Dietary Supplements
Today we are announcing that after careful review, the FDA has concluded that a new regulatory pathway for CBD is needed that balances individuals’ desire for access to CBD products with the regulatory oversight needed to manage risks.
On May 17, Colorado’s governor signed the groundbreaking Consumer Protections for Artificial Intelligence Act. The Act regulates...